Skip to content

Efficacy and Safety Study of FID 119515A

A Randomized, Observer-Masked, Efficacy and Safety Study of FID 119515A in Dry Eye

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01833117
Enrollment
75
Registered
2013-04-16
Start date
2013-05-31
Completion date
2013-06-30
Last updated
2018-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Keywords

Dry eye, Tear film, Tear break-up time, Ocular surface, Eye drops

Brief summary

The purpose of this study was to compare the effect of FID 119515A to Blink® Tears on the integrity of tear film in adults with a history of dry eye in both eyes.

Detailed description

Subjects who met the enrollment criteria were randomized in a 2:1 manner to receive treatment with FID 119515A or Blink® Tears respectively for this 1-day, single-dose study.

Interventions

OTHERFID 119515A

topical ocular drops

topical ocular drops

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Sign Informed Consent. * Best corrected visual acuity (BCVA) of 55 or greater in each eye as measured by an ETDRS chart (letters read method). * At least a 3 month documented history of dry eye in both eyes. * TBUT and Ocular Surface Disease Index (OSDI) Questionnaire score as specified in protocol. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Pregnant or breastfeeding. * Any evidence of ocular infection or inflammation within 30 days prior to Screening. * Any ocular surgery. * Ocular trauma requiring medical or pharmacological treatment within 1 year of Screening. * Current presence of punctal plugs (permanent or temporary) or previous permanent punctal closure by cautery/diathermy. * Use of topical ocular prescription or non-prescription medications within 30 days of Screening. * Participation in any other clinical trial within 30 days prior to Screening. * Other protocol-defined

Design outcomes

Primary

MeasureTime frameDescription
Mean Change From Baseline in Tear Break-up Time (TBUT) at 60 MinutesBaseline, 60 minutesFluorescein dye was instilled in the eye to assess tear break-up time. After instillation of the fluorescein, the subject was instructed to blink 3 times, then stare and not blink. The investigator measured the time from the last blink until the first black (dry) spot appeared in the precorneal tear film. Tear break-up time was assessed prior to test article instillation (baseline) and at 60 minutes. Three consecutive measurements were taken per eye at each time point, with the average of the 3 scores being the value analyzed. An increase in total score equates to improvement. One eye was chosen as the study eye and only data for the study eye were used.

Secondary

MeasureTime frameDescription
Area Under Curve (AUC) of TBUT From 0 to 60 Minutes0 to 60 minutesFluorescein dye was instilled in the eye to assess tear break-up time. After instillation of the fluorescein, the subject was instructed to blink 3 times, then stare and not blink. The investigator measured the time from the last blink until the first black (dry) spot appeared in the precorneal tear film. Tear break-up time was assessed prior to test article instillation (baseline) and at 5, 15, 30, and 60 minutes. Three consecutive measurements were taken per eye at each time point, with the average of the 3 scores being the value analyzed. An increase in total score equates to improvement. One eye was chosen as the study eye and only data for the study eye were used.

Participant flow

Recruitment details

Participants were recruited from 3 study centers located in the US.

Pre-assignment details

Of the 75 enrolled, 13 participants failed to meet inclusion/exclusion criteria and were exited as screen failures prior to randomization. This reporting group includes all enrolled and randomized participants (62).

Participants by arm

ArmCount
FID 119515A
FID 119515A, 1 drop instilled in the study eye, single dose
43
Blink
Blink® Tears, 1 drop instilled in the study eye, single dose
19
Total62

Baseline characteristics

CharacteristicBlinkFID 119515ATotal
Age, Continuous60.4 years
STANDARD_DEVIATION 14.48
54.6 years
STANDARD_DEVIATION 14.86
56.4 years
STANDARD_DEVIATION 14.87
Sex: Female, Male
Female
18 Participants32 Participants50 Participants
Sex: Female, Male
Male
1 Participants11 Participants12 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 430 / 19
serious
Total, serious adverse events
0 / 430 / 19

Outcome results

Primary

Mean Change From Baseline in Tear Break-up Time (TBUT) at 60 Minutes

Fluorescein dye was instilled in the eye to assess tear break-up time. After instillation of the fluorescein, the subject was instructed to blink 3 times, then stare and not blink. The investigator measured the time from the last blink until the first black (dry) spot appeared in the precorneal tear film. Tear break-up time was assessed prior to test article instillation (baseline) and at 60 minutes. Three consecutive measurements were taken per eye at each time point, with the average of the 3 scores being the value analyzed. An increase in total score equates to improvement. One eye was chosen as the study eye and only data for the study eye were used.

Time frame: Baseline, 60 minutes

Population: This analysis population includes all randomized participants.

ArmMeasureValue (MEAN)Dispersion
FID 119515AMean Change From Baseline in Tear Break-up Time (TBUT) at 60 Minutes1.2 secondsStandard Error 0.23
BlinkMean Change From Baseline in Tear Break-up Time (TBUT) at 60 Minutes1.2 secondsStandard Error 0.22
Secondary

Area Under Curve (AUC) of TBUT From 0 to 60 Minutes

Fluorescein dye was instilled in the eye to assess tear break-up time. After instillation of the fluorescein, the subject was instructed to blink 3 times, then stare and not blink. The investigator measured the time from the last blink until the first black (dry) spot appeared in the precorneal tear film. Tear break-up time was assessed prior to test article instillation (baseline) and at 5, 15, 30, and 60 minutes. Three consecutive measurements were taken per eye at each time point, with the average of the 3 scores being the value analyzed. An increase in total score equates to improvement. One eye was chosen as the study eye and only data for the study eye were used.

Time frame: 0 to 60 minutes

Population: This analysis population includes all randomized participants.

ArmMeasureValue (MEAN)Dispersion
FID 119515AArea Under Curve (AUC) of TBUT From 0 to 60 Minutes4.5 seconds x hoursStandard Deviation 0.22
BlinkArea Under Curve (AUC) of TBUT From 0 to 60 Minutes4.5 seconds x hoursStandard Deviation 0.21

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026